Merck Discontinues Phase 3 Trial of Combination Therapy
Late-Stage Study Evaluated Immunotherapy and Chemotherapy in First-Line Treatment
Merck (MRK), known as MSD outside of the United States and Canada, has announced the discontinuation of a Phase 3 clinical trial evaluating an investigational combination therapy for the first-line treatment of patients with a certain type of cancer. The decision was made after a review of the data from the trial, which suggested that the combination therapy was not meeting its primary endpoint.
The trial, which was conducted in collaboration with the Dana-Farber Cancer Institute, was evaluating the combination of Merck's anti-PD-1 therapy, Keytruda, with vibostolimab, an investigational anti-TIGIT antibody, and chemotherapy in patients with previously untreated metastatic squamous non-small cell lung cancer.
Merck said that it will continue to analyze the data from the trial to better understand the reasons for the discontinuation. The company also said that it remains committed to developing innovative therapies for patients with cancer.
Comments